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Abstract
Background: Posttraumatic stress disorder is an anxiety disorder characterized by deficits in the extinction of aversive
memories. Insulin-like growth factor 1 (IGF1) is the only growth factor that has shown anxiolytic and antidepressant
properties in human clinical trials. In animal studies, insulin-like growth factor binding protein 2 (IGFBP2) shows both IGF1dependent and IGF1-independent pharmacological effects, and IGFBP2 expression is upregulated by rough-and-tumble play
that induces resilience to stress.
Methods: IGFBP2 was evaluated in Porsolt, contextual fear conditioning, and chronic unpredictable stress models of
posttraumatic stress disorder. The dependence of IGFBP2 effects on IGF1- and AMPA-receptor activation was tested using
selective receptor antagonists. Dendritic spine morphology was measured in the dentate gyrus and the medial prefrontal
cortex 24 hours after in vivo dosing.
Results: IGFBP2 was 100 times more potent than IGF1 in the Porsolt test. Unlike IGF1, effects of IGFBP2 were not blocked by the
IGF1-receptor antagonist JB1, or by the AMPA-receptor antagonist 2,3-Dioxo-6-nitro-1,2,3,4 tetrahydrobenzo[f]quinoxaline-7sulfonamide (NBQX) in the Porsolt test. IGFBP2 (1 µg/kg) and IGF1 (100 µg/kg i.v.) each facilitated contextual fear extinction and
consolidation. Using a chronic unpredictable stress paradigm, IGFBP2 reversed stress-induced effects in the Porsolt, noveltyinduced hypophagia, sucrose preference, and ultrasonic vocalization assays. IGFBP2 also increased mature dendritic spine
densities in the medial prefrontal cortex and hippocampus 24 hours postdosing.
Conclusions: These data suggest that IGFBP2 has therapeutic-like effects in multiple rat models of posttraumatic stress
disorder via a novel IGF1 receptor-independent mechanism. These data also suggest that the long-lasting effects of IGFBP2
may be due to facilitation of structural plasticity at the dendritic spine level. IGFBP2 and mimetics may have therapeutic
potential for the treatment of posttraumatic stress disorder.
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Significance Statement
IGFBP2 has therapeutic potential for the treatment of PTSD and appears to produces its therapeutic-like effects by facilitating
brain plasticity.

Keywords: insulin-like growth factor binding protein 2, insulin-like growth factor I, posttraumatic stress disorder, dendritic
spines, resilience.

Introduction
Posttraumatic stress disorder (PTSD) is a major anxiety disorder that is characterized by deficits in the extinction of fearful
memories. PTSD affects as many as 30% of individuals that have
been directly associated with psychologically traumatic events
(Breslau et al., 1998). PTSD is considered a memory disorder in
which cues associated with the traumatic event form powerful sensory memories that are resistant to extinction (Parsons
and Ressler, 2013). Serotonin specific reuptake inhibitors (SSRIs)
are widely used to treat PTSD but with limited efficacy (Ipser et
al., 2015), thus there is a great unmet need for the treatment of
PTSD.
Growth factor receptor activation has been suggested to
have potential for treatment of PTSD (Duman and Monteggia,
2006; Soliman et al., 2010). Insulin-like growth factor I (IGF1) has
been approved by the FDA for human use in congenital dwarfism (NDA21-839) and has been reported to have both anxiolytic and antidepressant effects in humans when injected i.p.
(Thompson et al., 1998). IGF1 plasma levels are positively correlated with decreased expression of PTSD symptoms in humans
(Rusch et al., 2015). In addition, IGF1, brain derived neurotrophic
factor, and fibroblast growth factor have all been shown to be
decreased in depressed patients and elevated by treatment with
conventional antidepressants (Duman and Monteggia, 2006; Sen
et al., 2008).
Insulin-like growth factor binding protein 2 (IGFBP2) may
have therapeutic potential for the treatment of PTSD. IGFBP2 is
the predominant IGF1 binding protein in the brain and cerebrospinal fluid, is present at low levels in the periphery (Ocrant et
al., 1990; Poljakovic et al., 2006), and has been shown to cross the
blood-brain barrier (Huhtala et al., 2012). IGFBP2 has a molecular weight of 36 kD and has multiple biological effects, some of
which are independent of its binding to IGF1, mediated by different binding domains within IGFBP2 (Firth and Baxter, 2002; Azar
et al., 2014; Reyer et al., 2015). Rough-and-tumble play robustly
induces resilience to stress (Burgdorf et al., 2016) and upregulates IGFBP2 mRNA and protein levels in the medial prefrontal
cortex (Burgdorf et al., 2010).
PTSD can be modeled in rodents by measuring emotional
responses to stress and extinction of these behaviors. Key
symptoms of PTSD in humans are persistent recurrent thoughts
of traumatic events, especially when reexposed to cues,
and increased anxiety and depressive symptoms (American
Psychiatric Association, 2013). In rodents, fear extinction tasks
can model the persistence of cue-induced stress responses,
whereas repeated stress can model the anxiety and depression symptoms of PTSD (Burgdorf et al., 2015b). In these stress
models, increases in negative affect are measured by the Porsolt
and novelty-induced hypophagia tests, and decreases in positive affect/anhedonia are measured by the sucrose preference
test. In addition, the ultrasonic vocalization test measures both
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negative (20-kHz ultrasonic vocalization [USVs]) and positive
affect (50-kHz USVs).
Chronic unpredictable stress (CUS) can be used to test for
rapid-acting therapeutics for PTSD. CUS induces a long-lasting
and robust PTSD-like phenotype that models clinical features
of PTSD and has been well characterized at the behavioral, physiological, cellular, and molecular levels (Duman and
Aghajanian, 2012; Burgdorf et al., 2015b). CUS induces a behavioral phenotype that is responsive to chronic (3 weeks) but not
acute or short-term treatment with fluoxetine (Schmidt and
Duman, 2007) and is sensitive to rapid-acting therapeutics (Li
et al., 2010; Burgdorf et al., 2013). Thus, the CUS model provides
a rigorous paradigm for identifying compounds with rapid-acting therapeutic efficacy in PTSD, thereby differentiating IGF1
and IGFBP2 from the currently approved therapeutics for this
disorder.
The experiments in this study tested whether IGFBP2 has
therapeutic potential for the treatment of PTSD by using a contextual fear conditioning paradigm to measure extinction and
consolidation and a CUS paradigm to measure anxiety and
depressive-like symptoms of PTSD. IGFBP2 was chosen because
of its role in resilience to stress induced by positive affect
(Burgdorf et al., 2010). Since the behavioral effects of IGF1 are
known to be IGF1 and AMPA receptor dependent, we determined
whether the behavioral effects of IGFBP2 were also IGFIR and
AMPAR dependent. Finally, we performed dendritic spine analysis in the medial prefrontal cortex and hippocampus 24 hours
after dosing to determine whether changes in structural plasticity were associated with the long-lasting behavioral effects of
IGFBP2.

Materials and Methods
Animals
Adult male 2- to 3-month-old Sprague-Dawley (SD) rats from
Envigo Inc. were used. Rats were housed in Lucite cages with
aspen wood chip bedding, maintained on a 12:12 light:dark cycle
(lights on at 5 am), and given ad libitum access to Purina lab
chow and tap water throughout the study. All experiments were
approved by the Northwestern University Institutional Animal
Care and Use Committees.

Drugs
IGFBP2 was purchased from PeproTech, IGF1 was purchased
from Shenandoah Biotechnology, the IGF1 antagonist JB1 was
purchased from Sigma, and the AMPA/kainate receptor antagonist 2,3-Dioxo-6-nitro-1,2,3,4 tetrahydrobenzo[f]quinoxaline7-sulfonamide (NBQX) disodium salt was purchased from
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Abcam. Doses for IGF1 and IGFBP2 were determined by dose
response studies (Figure 1), and doses of JB1 and NBQX were
chosen from Burgdorf et al. (2015a). All drugs were administered
in sterile saline vehicle at a volume of 1 mL/kg.

Porsolt Test
Testing was conducted as described in Burgdorf et al. (2013,
2015a). Animals were placed in a 46-cm-tall x 20-cm-diameter
clear glass tube filled to 30 cm with tap water (23 ± 1°C) for 15
minutes on the first day (habituation) and 5 minutes on the subsequent test days at 1 hour postdosing for non-CUS-treated rats,
or during the last 5 minutes of the habituation trial for CUStreated rats 1 hour after dosing or 24 hours after the last roughand-tumble play session. Water was changed after every other
animal. Animals were videotaped. Immobility time was defined
as the minimal amount of effort required to keep the animals
head above water. Experiments were conducted in a blind manner and scored offline by an experimenter with high inter-rater
reliability (Pearson’s r > .9).

a single 5-minute Porsolt test session 1 hour after dosing (n = 8/
group).

Contextual Fear Extinction
Testing was conducted as previously described (Burgdorf et al.,
2015b), and the first extinction tests occurred 1 hour postdosing.
On the contextual fear training day (D0), animals were placed in
a Coulbourn Instruments shock chamber (40 × 40 × 40 cm) for
400 seconds and received three 0.5-mA 1-s footshocks delivered
to the floor bars at 90-, 210-, and 330-second timepoints. During
extinction, rats were subjected to daily 5-minute nonreinforced
(no shock) extinction trials for the first 6 days after training and
on day 14 posttraining (consolidation trial). Freezing was quantified via FreezeFrame software (Actimetrics) during the last 3
minutes of each extinction trial. Animals were dosed with a single optimal dose of IGFBP2 (1 µg/kg i.v.), IGF1 (100 µg/kg i.v.), or
sterile saline vehicle (1 mL/kg i.v.) 1 hour before the first extinction session (n = 9–11/group).

CUS Procedures
JB1 Studies
The day after Porsolt habituation, non-CUS rats were dosed with
IGFBP2 (1 μg/kg i.v.), the IGF1R antagonist JB1 (0.5 mg/kg i.v.), coadministration of both IGFBP2 and JB1, or sterile saline vehicle
(1 mL/kg i.v.). All animals received a single 5-minute Porsolt test
session 1 hour postdosing (n = 6–8/group).

NBQX Studies
The day after Porsolt habituation, non-CUS-treated rats were
dosed with IGFBP2 (1 μg/kg i.v.) or sterile saline vehicle (1 mL/kg
i.v.). NBQX (10 mg/kg i.p.) or sterile saline vehicle (1 mL/kg i.p.)
was coadministered with IGFBP2 or vehicle. All animals received

Rats were exposed to a CUS protocol previously shown to elicit
depression-like symptoms in rats (Li et al., 2011; Burgdorf et al.,
2015a). Animals received 21 days of CUS before dosing and continued to receive CUS until the animals were killed 1 day after
the last behavioral test (total of 37 days of CUS). A total of 9 different CUS stressors were used (2 stressors/d). The stressors
(days) included rotation on a shaker for 1 hour (3, 9, 13, 19, 24,
28, 33, 37), placement in a 4°C ambient for 1 hour (1, 5, 12, 14,
18, 22, 26, 30, 36), lights off for 3 hours from 10:00 am to 1:00 pm
(2, 10, 17, 23, 31, 34, 37), lights on overnight (1, 5, 8, 13, 16, 22, 32,
34), strobe light overnight (3, 6, 9, 14, 17, 20, 23, 28, 31, 33), 45°
tilted cages overnight (4, 7, 11, 15, 18, 21, 25, 29, 35), food and
water deprivation overnight (2, 6, 10, 15, 19, 26, 27, 30), crowded
housing overnight (4, 7, 11, 16, 21, 25, 29, 35), and isolation housing overnight (8, 12, 20, 24, 27, 32, 36). Animals in the no-CUS
group (n = 9) were weighed every 4 days and received behavioral
testing without additional stressors. Animals in the CUS groups
received a single optimal dose of IGFBP2 (1 μg/kg i.v.; n = 8) or
sterile saline vehicle (n = 10).

Sucrose Preference Test
Testing was conducted as described in Li et al., 2011 and Burgdorf
et al., 2015a, and testing occurred 3 days postdosing or after the
last rough-and-tumble play session. Rats were exposed to a palatable sucrose solution (1%; Sigma) for 48 hours, followed by 4
hours of water deprivation and a 1-hour exposure to 2 identical
bottles, one filled with sucrose solution and the other with tap
water. Sucrose preference was defined as the ratio of the volume
of sucrose vs total volume of sucrose and water consumed during the 1-hour test.

Novelty-Induced Hypophagia (NIH) Test

Figure 1. A single i.v. dose of insulin-like growth factor binding protein 2 (IGFBP2)
produces therapeutic-like effect in the Porsolt test with 100-fold greater potency
than insulin-like growth factor I (IGF1). Mean ± SEM immobility time in nonchronic unpredictable stress (CUS)-exposed rats treated with a single injection
of IGFBP2 (0.3 to 10 µg/kg i.v.), IGF1 (30–1000 µg/kg i.v.), or saline vehicle (1 mL/kg)
and tested 1 hour postdosing. *P < .05 Fisher’s PLSD posthoc test vs vehicle. n = 7
to 8/group. Data for IGF1 was adapted from Burgdorf et al. (2015a).
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Testing was conducted as described in Burgdorf et al., 2013,
2015a, and testing occurred 2 days postdosing or after the last
rough-and-tumble play session. Animals were food deprived
on the night before testing, and lab chow was placed into the
center chamber of the open field (40 x 40 x 20 cm) for 10 minutes
under dim-red lighting. Between animals, feces and urine were
removed from the apparatus. Immediately after NIH testing,
the latency to eat in the animal’s home cage was determined
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as a control. Animals were videotaped and latency (in seconds)
for the animal to take the first bite of food, as well as locomotor
activity (in line crosses), was scored offline by an experimenter
blinded to the treatment condition.

USV Test
Heterospecific rough-and-tumble play was conducted as previously described (Burgdorf et al., 2013, 2015a), and testing
occurred 3 hours and postdosing or 1 day after the last roughand-tumble play session. Heterospecific rough-and-tumble play
stimulation was administered by the experimenter’s right hand.
The experimenter was blind to the treatment condition of the
animals. Animals received 3 minutes of heterospecific roughand-tumble play consisting of alternating 15-second blocks of
heterospecific play and 15 seconds of no-stimulation. Highfrequency USVs were recorded and analyzed by sonogram in
a blind manner as described previously (Burgdorf et al., 2011).
Animals were not habituated to play stimulation before dosing and testing. Using this paradigm, we have shown that the
increase in 50-kHz USVs that occurs across trial blocks reflects
positive emotional learning (Burgdorf et al., 2011).

Dendritic Spine Morphology Analysis
Dendritic spine analyses were conducted as described in
Burgdorf et al., 2015c. Animals were dosed with a single dose
of IGFBP2 (1 µg/kg i.v.), IGF1 (100 µg/kg i.v.), or 0.9% sterile
saline vehicle (1 mL/kg), and 24 hours postdosing they were
deeply anesthetized (isoflurane) and brains fixed via cardiac
perfusion using 4% paraformaldehyde. Brains were stored in
ice cold 0.1 M phosphate buffer and stored at 4°C until sectioning. Brains were sectioned using a tissue Vibratome (Leica
VT1000) to collect sections (300 μm thick) from the anterior
to posterior extremes of each brain. Ballistic dye labeling (DiI
and DiO; 3 mg dissolved in methylene chloride and coated on
tungsten particles) was performed using a commercially available gene gun (Bio-Rad, Hercules, CA) to label target neurons.
Thick sections were mounted to slides with raised barriers
using ProLong Gold (Life Technologies, Gaithersburg, MD) and
cover slipped. Laser‐scanning confocal microscopy (Olympus
FV1000) was performed using a 63× objective (1.42 NA) to scan
individually labeled neurons at high resolution (0.103- × 0.103× 0.33-μm voxels). Target neurons were identified in the brain
regions of interest by anatomical location and cell morphology.
Microscopy was performed blind to experimental conditions. A
minimum of 5 cells per animal were sampled from each of the
2 regions. For medial prefrontal cortex (MPFC), samples (50 μm)
were collected from proximal tufts. Two positions from dentate
granule neurons in the hippocampus were selected based on
well-described discriminate connectivity between these laminae (Llorens-Martín et al. 2014): (1) primary dendrites within
the inner molecular layer, and (2) secondary dendrites from the
middle molecular layer. For dentate granule neurons, samples
(50 μm) were collected from primary dendrites starting at 100
μm from the soma or the secondary dendrites 50 μm from the
branch point.
Blind deconvolution (AutoQuant) was applied to raw
3‐dimensional digital images that were then analyzed for spine
density and morphology by trained analysts. Individual spines
were measured manually for head diameter, spine length, and
spine neck diameter from image Z-stacks using software custom-designed by Afraxis Inc. Each dendrite was analyzed by 3 to
4 independent analysts. Automated image assignment software
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(C++) distributed images to analysts in a randomized manner and ensured that each analyst performed measurements
of near equal numbers of dendrites per group. Analysts were
blinded to all experimental conditions (including treatment,
brain region, and cell type). Statistical analysis of interanalyst
variability for each dendrite was examined online and used to
eliminate dendrites that did not meet interanalyst reliability
criteria. For spine density and spine morphological classification, data across analysts were averaged to report data for each
dendrite. Identification, measurement, and classification of dendritic spines were performed as previously described (Ota et al.,
2014). For the purposes of the current study, we have denoted
thin spines as “immature” to underscore their vulnerability
to modification and role in recent encoding processes relative
to more “mature” classes (i.e., mushroom and stubby classes),
which are more closely associated with long-term memory
storage (Young et al., 2014). Data population values (n’s) were
reported for dendrites collected equally from all rats.

Statistical Analysis
Data were analyzed by ANOVA, followed by Fisher’s PLSD posthoc test (Statview). The level of statistical significance was set
at P < .05.

Results
IGFBP2 Is 100 Times More Potent Than IGF1 in
the Porsolt Test and Is IGF1- and AMPA-Receptor
Independent
IGFBP2 (0.3 to 10 μg/kg i.v.) reduced immobility time in the
Porsolt test 1 hour postdosing [F(4, 31) = 51.99, P < .05; Fisher’s
PLSD posthoc test all IGFBP2 doses vs vehicle] (Figure 1). The lowest maximally effective dose of IGFBP2 was 1 μg/kg i.v. [Fishers
PLSD posthoc test 0.3 vs 10, P < .05; 0.3 vs all other IGFBP2 doses,
P < .001]. However, unlike IGF1, the antidepressant-like effect
of IGFBP2 was not blocked by coadministration of either JB1 or
NBQX [F(3,32) = 129.17, P < .0001; Fisher’s PLSD posthoc test for
vehicle vs all other treatments] (Figure 2).

A Single Dose of IGFBP2 or IGF1 Facilitated
Contextual Fear Extinction and Consolidation
IGFBP2 (1 μg/kg iv) or IGF1 (100 μg/kg iv) facilitated contextual fear
extinction as measured by reduced freezing time [F(2, 28) = 8.80,
P < .05; Fisher’s PLSD posthoc test IGFBP2 or IGF1 vs vehicle from
repeated-measures ANOVA analysis; P < .05; Fisher’s PLSD posthoc test IGFBP2 vs vehicle for D1-6 and D14, and IGF1 vs vehicle
for D2-6 and D14 Fisher’s PLSD posthoc test on individual test
days] (Figure 3A). IGFBP2 or IGF1 also facilitated contextual fear
consolidation as measured by the change in freezing score from
the last extinction day (D6) compared with the consolidation
day 14 [F(2, 28) = 5.99, P < .05; Fisher’s PLSD posthoc test IGFBP2
or IGF1 vs vehicle] (Figure 3B).

A Single i.v. Dose of IGFBP2 Produces a Rapid-Acting
and Long-Lasting Therapeutic-Like Effect in a CUS
Model of PTSD
IGFBP2 (1 μg/kg, i.v.) treatment in rats exposed to CUS significantly reduced immobility time in the Porsolt test (1 hour
postdosing) compared with CUS-treated vehicle rats, and CUS
vehicle rats showed increased immobility times compared with
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Figure 2. The therapeutic-like effects of insulin-like growth factor I (IGF1), but not insulin-like growth factor binding protein 2 (IGFBP2), are IGF1R- and AMPA-receptor
(AMPAR) dependent. (A) Mean ± SEM immobility time in non-chronic unpredictable stress (CUS)-exposed rats treated with a single i.v. injection of IGF1 (100 µg/kg),
coadministration of IGF-1 and JB1 (0.5 mg/kg i.v.) or NBQX (10 mg/kg i.p.), or saline vehicle (1 mL/kg), and tested 1 hour postdosing. (B) Mean ± SEM immobility time
in non-CUS-exposed rats treated with a single i.v. injection of IGFBP2 (1 µg/kg i.v.), coadministration of IGFBP2 and JB1 (0.5 mg/kg, i.v.), or 2,3-Dioxo-6-nitro-1,2,3,4
tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX) (10 mg/kg, i.p.), or saline vehicle (1 mL/kg) and tested 1 hour postdosing. *P < .05 Fisher’s PLSD posthoc test vs
vehicle. n = 6 to 9/group. Data for IGF1 were adapted from Burgdorf et al. (2015a).

Figure 3. A single dose of insulin-like growth factor binding protein 2 (IGFBP2) or insulin-like growth factor I (IGF1) facilitated contextual fear extinction and consolidation. Mean ± SEM percent time freezing in animals dosed with IGFBP2 (1 µg/kg i.v.), IGF1 (100 µg/kg i.v.), or sterile saline vehicle (1 mL/kg i.v.) 1 hour before extinction
day 1. Three shocks (0.5 mA, 1 s) were administered 90, 210, and 330 s after animals were placed in the conditioning chamber on D0. (A) During extinction, rats were
submitted to a 5-minute nonreinforced test trial every 24 hours for 6 consecutive days (D1-6), and on day 14 postconditioning (the consolidation trial) and freezing was
quantified via FreezeView software and was measured during the last 3 minutes of each trial. (B) Consolidation was measured by the increase in freezing behavior on
the last extinction day compared with the consolidation day (D14-D6). n = 9–11 rats/group. *P < .05 Fisher’s PLSD posthoc test vs vehicle.

no-CUS-treated rats [F(2, 21) = 63.61, P < .0001; Fisher’s PLSD
posthoc test IGFBP2 vs vehicle, or vehicle vs no-CUS control, P <
.0001] (Figure 4A). Furthermore, IGFBP2 increased sucrose preference scores in CUS-treated rats (4 days postdosing) compared
with CUS-treated vehicle rats, while CUS vehicle-treated rats
showed significantly decreased sucrose preference scores compared with no-CUS-treated rats [F(2, 21) = 14.3, P = .0001; Fisher’s
PLSD posthoc test IGFBP2 vs vehicle, P < .0001; vehicle vs no-CUS
control, P < .01] (Figure 4B).
IGFBP2 also significantly decreased feeding latency in a novel
environment in the NIH test (2 days postdosing) compared with
CUS-treated vehicle rats, while CUS vehicle rats showed longer
feeding latencies compared with no-CUS-treated rats [F(2,
21) = 7.78, P < .01; Fisher’s PLSD posthoc test IGFBP2 vs vehicle,
vehicle vs no-CUS control, P < .01], while no changes were seen
in latency to eat in the homecage [F(2, 26) = 0.4, P > .05; data not
shown] or line crosses in the novel environment [F(2, 26) = 0.3,
P > .05; data not shown] (Figure 4C).
Finally, IGFBP2 increased weight gain (1 week postdosing)
compared with CUS-treated vehicle rats, while CUS vehicle rats
showed decreased weight gain compared with no-CUS-treated
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rats [F(2, 21) = 7.78, P < .01; Fisher’s PLSD posthoc test IGFBP2 vs
vehicle, vehicle vs no-CUS control, P < .01] (Figure 4D).

IGFBP2 Reversed CUS-Induced Deficits in Positive
Emotional Learning
IGFBP2 in CUS-treated rats increased rates of hedonic 50-kHz
USVs in response to a temporal CS that predicted heterospecific
play (positive emotional learning) compared with vehicle CUStreated rats, and CUS vehicle rats showed decreased CS-elicited
hedonic 50-kHz USVs compared with no-CUS-treated rats [F(2,
21) = 7.19, P < .01; Fisher’s PLSD posthoc test IGFBP2 vs vehicle,
vehicle vs no-CUS control, P < .01] (Figure 4E). IGFBP2 in CUStreated rats increased rates of hedonic USVs (Figure 4F) and
reduced rates of aversive 20 kHz (Figure 4G) compared with
vehicle CUS-treated rats, while CUS vehicle-treated rats showed
decreased hedonic 50-kHz USVs and increased aversive 20-kHz
USVs compared with no-CUS-treated rats [hedonic USVs F(2,
21) = 58.59, P < .0001; Fisher’s PLSD posthoc test IGFBP2 vs vehicle,
vehicle vs no-CUS control, P < .0001; aversive USVs F(2, 21) = 8.29,
P < .01 Fisher’s PLSD posthoc test IGFBP2 vs vehicle, vehicle vs
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Figure 4. Insulin-like growth factor binding protein 2 (IGFBP2) produces therapeutic-like effects in a chronic unpredictable stress (CUS) model of posttraumatic stress
disorder (PTSD). (A) Mean ± SEM immobility time in the Porsolt forced swim test (FS) in naïve (n = 8) and CUS-exposed (n = 8) rats, and CUS-exposed (n = 8) rats that were
pretreated with IGFBP2. (B) Mean ± SEM sucrose preference (SP) in the sucrose preference test. (C) Mean ± SEM latency to feed in the novelty induced hypophagia (NIH)
test. (D) Mean ± SEM change in body weight (compared with CUS day 0). (E) Mean ± SEM hedonic 50-kHz ultrasonic vocalizations (USVs) in response to a conditioned
stimuli that predicts heterospecific play. Mean ± SEM hedonic 50-kHz (F) and aversive 20-kHz (G) USVs. (H) Mean ± SEM running speed to self-administer heterospecific
play. n = 8/group. *P < .05 Fisher’s PLSD posthoc test vs no-CUS group; #P < .05 Fisher’s PLSD posthoc test vs CUS group.

no-CUS control, P < .01]. As shown in Figure 4H, IGFBP2 in CUStreated rats also significantly increased running speed to selfadminister heterospecific play vehicle CUS-treated rats, while
CUS vehicle rats showed decreased running speed compared
with no-CUS-treated rats [F(2, 26) = 32.72, P < .0001; Fisher’s PLSD
posthoc test IGFBP2 vs vehicle, vehicle vs no-CUS control, P <
.0001].

In No-CUS Rats, IGFBP2 Was Active in the Porsolt,
Sucrose Preference, NIH, and Positive Emotional
Learning Tests, but Did Not Alter Body Weight
In no-CUS rats, IGFBP2 (n = 9) compared with vehicle (n = 9)
reduced immobility time in the Porsolt test [F(1, 16) = 40.1, P
< .0001; supplemental Figure 2A], increased sucrose preference [F(1, 16) = 6.2, P < .05; supplemental Figure 2B], decreased
feeding latency in the NIH test [F(1, 16) = 19.0, P < .001; supplemental Figure 2C], increased positive emotional learning
during the final 2 testing blocks [F(1, 16) = 10.5, P < .01; supplemental Figure 2E], increased total hedonic USVs [F(1, 16) =
59.0, P < .0001; supplemental Figure 2F], reduced total aversive
USVs [F(1, 16) = 12.0, P < .001; supplemental Figure 2G], and
increased the rewarding value of play as indexed by running
speed [F(1, 16) = 6.9, P < .05; supplemental Figure 1H] but did not
alter body weight gain 7 days postdosing [F(1, 16) = 1.6, P > .05;
supplemental Figure 1D]. Although the vehicle non-CUS values
appear to be closer to the vehicle CUS values of the previous
experiment, they were within the range of non-CUS control
values based on previous studies using these assays (Burgdorf
et al., 2009, 2011, 2013).
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IGFBP2 Increased Mature Spine Density in MPFC
Layer V Pyramidal Neurons, and Both IGFBP2 and
IGF1 Increased the Density of Mature Spines and
Total Spines in Dentate Granule Neurons of the
Hippocampus
IGFBP2 increased the density of mature mushroom spines in
MPFC layer V pyramidal neuron proximal tufts [F(2, 77) = 3.4, P <
.05; Fisher’s PLSD posthoc test IGFBP2 vs vehicle] but did not alter
the density of other spine types or the total number of spines
in this region (all P >.05) (Figure 5A). IGF1 increased the density
of mature stubby spines and the total number of spines in the
inner molecular layer of the dentate gyrus [stubby spines - F(2,
71) = 3.7, P < .05; Fisher’s PLSD posthoc test IGF1 vs vehicle; total
spines - F(2, 71) = 3.9, P < .05; Fisher’s PLSD posthoc test IGF1 vs
vehicle], while the other spine types did not change (all Ps > 0.05)
(Figure 5B). Lastly, IGFBP2 increased the density of mature stubby
spines and the total number of spines in the middle molecular
layer of the dentate gyrus [stubby spines - F(2, 70) = 3.3, P < .05;
Fisher’s PLSD posthoc test IGFBP2 vs vehicle; total spines - F(2,
71) = 3.5, P < .05; Fisher’s PLSD posthoc test IGFBP2 vs vehicle],
while the other spine types did not change (all P > .05) (Figure 5C).

Discussion
The data presented here demonstrate that a single dose of
IGFBP2 (1 µg/kg i.v.) can induce rapid- and long-lasting effects in
multiple rat models of PTSD. These effects of IGFBP2 were IGF1
and AMPA receptor independent. The effects of IGFBP2 may not
be due to direct interactions with CUS-induced mechanisms
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Figure 5. Insulin-like growth factor binding protein 2 (IGFBP2) (1 µg/kg i.v.) and insulin-like growth factor I (IGF1) (100 µg/kg i.v.) differentially increased the density
of mature dendritic spines and total spine density in either the MPFC or hippocampus 24 hours postdosing. In male 2- to 3-month-old rats. (A) IGFBP2 (1 µg/kg i.v.)
significantly increased the density of mature mushroom spines in MPFC layer V tufts; (B) IGF1 (100 µg/kg i.v) increased the density of mature stubby spines as well as
total spine density in the primary apical dentate gyrus (100–150 μM from the dendrite). (C) IGFBP2 increased the density of mature stubby spines as well as total spine
density in the secondary apical dentate gyrus (50 μM from the dendritic branch). Mean ± SEM. n = 17 to 31 cells/group (n = 3–4 rats/group; 716–1333 spines/group), *P <
.05 Fisher’s PLSD posthoc test vs vehicle.

leading to pathophysiology, since the same drug effects were
seen in non-CUS rats (supplemental Figure 2). However, given
that each of the non-CUS models used in the present studies
experienced a preexposure stress (iv injection), IGFBP2 may
reverse the effects of both acute and chronic stress. Both fluoxetine and ketamine are clinically effective treatments for PTSD
(Connor et al., 1999; Feder and Murrough, 2015) and in preclinical models can reverse the effects of both acute stress and CUS
(Cryan et al., 2005; Willner, 2005; Li et al., 2010, 2011). The behavioral effects of IGFBP2 were also associated with increased structural plasticity as measured by mature dendritic spine density
in the medial prefrontal cortex and hippocampus. These data
suggest that the therapeutic effects of IGFBP2 are mediated by a
novel pharmacological pathway.
Both IGFBP2 and IGF1 show unique rapid-acting and longlasting therapeutic-like effects in multiple models of PTSD. SSRIs
are typically used to treat PTSD but have limited efficacy, require
3 to 4 weeks of daily dosing to show maximal efficacy, and are
not as effective in treating anhedonia symptoms (Knutson et al.,
1998; Ipser et al., 2015). Recently, ketamine has been shown
to have rapid-acting therapeutic effects in PTSD (Feder and
Murrough, 2015); however, the addictive and psychotomimetic
properties of ketamine limits its widespread therapeutic use.
Exposure therapy is an extinction-based psychotherapy that is
widely used for the treatment of PTSD (Bisson et al., 2013); however, the therapeutic effects wane after treatment has terminated (Tarrier and Sommerfield, 2004), thus demonstrating poor
consolidation. In contrast, the therapeutic-like effects of IGFBP2
and IGF1 occur as early as 1 hour and last at least 2 weeks after
a single dose and show efficacy in the learning paradigms, as
well as in the positive and negative affective symptoms of PTSD.
Therapeutic doses of IGFBP2 and IGF1 are not associated with
psychotomimetic side effects such as changes in locomotor
activity. Lastly, the therapeutic-like effects of IGFBP2 and IGF1
are maintained during the consolidation period after extinction
training has ended.
These data suggests that IGFBP2 induces its therapeuticlike effects in PTSD via a novel mechanism. Although IGFBP2
is an IGF1 chaperone, it has also been shown to have IGF1independent effects via interaction with non-IGF1 binding
domains (Reyer et al., 2015). The effects of IGF1 are due to activation of the IGF1 receptor, followed by downstream AMPA
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receptor activation (Burgdorf et al., 2015a). In contrast to IGF1,
the therapeutic-like effects of IGFBP2 in the Porsolt test were
not blocked by either an IGF1 or AMPA receptor antagonist. It
is likely that NBQX or JB1 would not block the effects of IGFBP2
in fear extinction/consolidation given that the mechanism of
action of IGFBP2 may be shared across PTSD-related behaviors.
In addition, IGFBP2 was 100 times more potent than IGF1 in the
PTSD models used. IGFBP2 is a relatively large circulating protein (36 kD) with multiple binding domains, and it appears likely
that the behavioral effects of IGFBP2 are due to interaction with
a novel target via a non-IGF1 binding domain.
Structural plasticity may underlie the long-lasting effects
of IGFBP2 and IGF1. Fluoxetine and ketamine have been shown
to increase mature dendritic spine density in the hippocampus and/or medial prefrontal cortex. While ketamine increases
immature spines, mature spines, and total number of spines (Li
et al., 2010, 2011), chronic fluoxetine treatment increases both
the density and proportion of mature spines without affecting
total spine number (Ampuero et al., 2010). In contrast, IGFBP2
and IGF1 show a third pattern of spine alterations: an increase
in only mature dendritic spines, with a concomitant increase in
total spine number. The increase in structural plasticity induced
by IGF1 and ketamine is also associated with an enhancement
in metaplasticity, that is, a lowered threshold for plastic changes
in synapse strength, measured as an increased magnitude of
LTP induced in slices 24 hours postdosing (Burgdorf et al., 2013,
2015b, 2015c; Graef et al., 2015). In addition, the effects of IGF1
and IGFBP2 are region dependent and are mainly seen in the
MPFC, a structure widely implicated in PTSD/anxiety disorders (Shin and Liberzon, 2010). Future studies should examine
the effect of IGFBP2 on LTP, metaplasticity, and dendritic spine
dynamics in CUS-treated rats to evaluate the therapeutic potential of IGFBP2.
The findings reported here suggest that IGFBP2 may have
therapeutic value for the treatment of PTSD, and that IGFBP2
produces these effects via a novel mechanism of action. Future
studies will be needed to determine which binding domain(s)
of IGFBP2 are responsible for its therapeutic-like effects, and
the site(s) of action responsible for these effects. In addition,
other IGFBPs should be examined given that some of them
have been shown to have protective effects in stress as well as
hypoxia-ischemia, which could be relevant to PTSD (Guan, 2011;
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Basta-Kaim et al., 2014). Thus, IGFBP2 and mimetics offer the
potential for a new generation of therapeutics for PTSD.

Supplementary Material
Supplementary data are available at International Journal of
Neuropsychopharmacology online.
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